Physician profile
Miriah Ashlie Roach
NPI 1801785977
$305.85
in general payments reported to CMS, 2019-2025
11 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $68.96 | 2025 | |
| Glaxosmithkline, LLC. | $46.60 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $29.37 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $25.68 | 2025 | Rexulti |
| Lilly USA, LLC | $24.82 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $20.94 | 2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.78 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.24 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $18.06 | 2025 | Gemtesa |
| Exact Sciences Corporation | $17.60 | 2025 | The Cologuard Plus Collection Kit |
| Tandem Diabetes Care, INC. | $14.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriah Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.